Search research articles
Contact Us
Filters
Showing results (371-380 of 436) with videos related to
Page
of 44
Sort By:
Annals of the Rheumatic Diseases
|
June 5, 2026
Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis
Tommy K Annfeldt, Mina N Händel, Tobias Haugegaard, et al.
Seminars in Arthritis and Rheumatism
|
January 6, 2026
Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study
Ying-Ying Leung, Tobias Haugegaard, Tommy Kok Annfeldt, et al.
The Journal of Rheumatology
|
May 3, 2019
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials
Louise Klokker, Dorthe B Berthelsen, Thasia Woodworth, et al.
Seminars in Arthritis and Rheumatism
|
October 18, 2017
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative
Pil Højgaard, Louise Klokker, Ana-Maria Orbai, et al.
The Journal of Rheumatology
|
May 3, 2017
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group
Alexis Ogdie, Maarten de Wit, Kristina Callis Duffin, et al.
Annals of the Rheumatic Diseases
|
September 11, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
Peter C Taylor, Michael E Weinblatt, Iain B McInnes, et al.
The Journal of Rheumatology
|
August 4, 2004
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial
Joel Kremer, Mark Genovese, Grant W Cannon, et al.
The Journal of Rheumatology. Supplement
|
June 3, 2018
Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
Richard Holland, William Tillett, Alexis Ogdie, et al.
The Journal of Rheumatology
|
August 3, 2017
Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets
Sean R Tunis, Lara J Maxwell, Ian D Graham, et al.
The Journal of Rheumatology. Supplement
|
June 2, 2021
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group
Ying Ying Leung, Ana-Maria Orbai, William Tillett, et al.
Page
of 44
Search research articles
Search
Showing results (371-380 of 436) with videos related to
Sort By:
Page
of 44
Annals of the Rheumatic Diseases
|
June 5, 2026
Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis
Tommy K Annfeldt, Mina N Händel, Tobias Haugegaard, et al.
Seminars in Arthritis and Rheumatism
|
January 6, 2026
Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study
Ying-Ying Leung, Tobias Haugegaard, Tommy Kok Annfeldt, et al.
The Journal of Rheumatology
|
May 3, 2019
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials
Louise Klokker, Dorthe B Berthelsen, Thasia Woodworth, et al.
Seminars in Arthritis and Rheumatism
|
October 18, 2017
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative
Pil Højgaard, Louise Klokker, Ana-Maria Orbai, et al.
The Journal of Rheumatology
|
May 3, 2017
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group
Alexis Ogdie, Maarten de Wit, Kristina Callis Duffin, et al.
Annals of the Rheumatic Diseases
|
September 11, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
Peter C Taylor, Michael E Weinblatt, Iain B McInnes, et al.
The Journal of Rheumatology
|
August 4, 2004
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial
Joel Kremer, Mark Genovese, Grant W Cannon, et al.
The Journal of Rheumatology. Supplement
|
June 3, 2018
Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
Richard Holland, William Tillett, Alexis Ogdie, et al.
The Journal of Rheumatology
|
August 3, 2017
Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets
Sean R Tunis, Lara J Maxwell, Ian D Graham, et al.
The Journal of Rheumatology. Supplement
|
June 2, 2021
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group
Ying Ying Leung, Ana-Maria Orbai, William Tillett, et al.
Page
of 44